Longitudinal SPECT study in Alzheimer's disease: Relation to apolipoprotein E polymorphism

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 6, 1998, Pages 742-746

  Lehtovirta, M ^a   Kuikka, J ^a   Helisalmi, S ^a   Hartikainen, P ^a   Mannermaa, A ^a   Ryynanen M ^a   Riekkinen, P Sr ^a   Soininen, H ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; Apolipoprotein E; SPECT

Indexed keywords

APOLIPOPROTEIN E; RESTRICTION ENDONUCLEASE;

ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; DISEASE SEVERITY; FRONTAL CORTEX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031778456     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.6.742     Document Type: Article

References (47)

1. Rossor M, Iversen L, Reynolds G. Neurochemical characteristics of early and late onset types of Alzheimer's disease. BMJ 1984;288:961-4.
2. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 1985;35:453-61.
3. Rossor M. Molecular pathology of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1993;56:583-6.
4. Sandbrink R, Hartmann T, Masters CL, et al. Genes contributing to Alzheimer's disease. Molecular Psychology 1996;1:27-40.
5. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
6. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein 4 allele in patients with Alzheimer's disease. Ann Neurol 1993;34:752-4.
7. Saunders A, Strittmatter W, Schmechel D, et al. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
8. Lehtovirta M, Helisalmi S, Mannermaa A, et al. Apolipoprotein E polymorphism and Alzheimer's disease in eastern Finland. Neurosci Lett 1995;185:13-5.
9. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 1994;125: 163-71.
10. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. TINS 1994;17:525-30.
11. Soininen H, Kosunen O, Helisalmi S, et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein 4 allele. Neurosci Lett 1995;187:79-82.
12. Burns A, Philpot M, Costa D, et al. The investigation of Alzheimer's disease with single photon emission tomography. J Neurol Neurosurg Psychiatry 1989;52:248-53.
13. 99Tcm-HMPAO in Alzheimer's disease. Nucl Med Commun 1992;13:535-41.
14. O'Brien JT, Eagger S, Syed GMS, et al. A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1992;55:1182-7.
15. Najlerahim A, Bowen D. Biochemical measurements in Alzheimer's disease reveal a necessity for improved neuroimaging techniques to study metabolism. Biochem J 1988;251:305-8.
16. Eberling JL, Jagust WJ, Reed BR, et al. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol Aging 1992;13:483-91.
17. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273: 942-7.
18. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 1996;334:752-8.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-14.
20. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
21. Reisberg B, Schneck MK, Ferris SH. The brief cognitive rating scale (BCRS): findings in primary degenerative dementia (FDD). Psychopharmacol Bull 1983;19:734-9.
22. Webster DD. Clinical analysis of the disability on Parkinson's disease. Mod Treat 1968;5:257-62.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
24. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-8.
25. Kuikka J, Tenhunen-Eskelinen M, Jurvelin J, et al. Physical performance of the Siemens multiSPECT 3 gamma camera. Nucl Med Commun 1993;14:490-7.
26. 99mTc-HMPAO SPECT differs in subgroups of Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1995;9:95-109.
27. Brun A, Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 1981;5:549-64.
28. Hixon JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990;31:545-8.
29. Tsukamoto K, Watanabe T, Matsushima T, et al. Determination by PCR-RFLP of apoE genotype in a Japanese population. J Lab Clin Med 1993;121:598-602.
30. Lehtovirta M, Laakso MP, Soininen H, et al. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995;67:65-72.
31. Johnson K, Mueller S, Walshe T, et al. Cerebral perfusion imaging in Alzheimer's disease. Arch Neurol 1987;44:165-8.
32. Perani D, Di Piero V, Vallar G, et al. Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease. J Nucl Med 1988;29:1507-14.
33. Frackowiak R, Pozzilli C, Legg N, et al. Regional cerebral oxygen supply and utilisation in dementia. Brain 1981;104: 753-78.
34. Habert M, Spampinato U, Mas J, et al. A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia. Eur J Nucl Med 1991; 18:3-11.
35. Reed T, Carmelli D, Swan G, et al. Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E 4 allele. Arch Neurol 1994;51:1189-92.
36. Bondi MW, Salmon DP, Monsch AU, et al. Episodic memory changes are associated with the APOE-ε4 allele in non-demented older adults. Neurology 1995;45:2203-6.
37. Soininen H, Partanen K, Pitkänen A, et al. Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: correlation to visual and verbal memory. Neurology 1994;44:1660-8.
38. Brown DRP, Hunter R, Wyper R, et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. J Pychiatr Res 1996;30:109-26.
39. Goodglass H, Kaplan E. The assessment of aphasia and related disorders. Philadelphia: Lea and Febiger, 1983.
40. Wechsler D. WAIS-R manual. New York: Psychological Corporation, 1981.
41. Helkala E-L, Laulumaa V, Soininen H, et al. Recall and recognition on memory in patients with Alzheimer's and Parkinson's diseases. Ann Neurol 1988;24:214-7.
42. Wechsler D. A standardised memory scale for clinical use. J Psychol 1945;19:87-95.
43. Russell EW. A multiple scoring method for assessment of complex memory functions. J Consult Clin Psychol 1975;43: 800-9.
44. Albin RL, Minoshima S, D'Amato CJ, et al. Fluorodeoxyglucose positron emission tomography in diffuse Lewy-body disease. Neurology 1996;47:462-6.
45. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994;5:747-9.
46. Sato A, Sato Y. Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain. Neurosci Res 1992;14:242-74.
47. McCormick DA. Cellular mechanisms of cholinergic control of neocortical and thalamic neuronal excitability. In: Steriade M, Biesold D, eds. Brain cholinergic systems. New York: University Press, 1990:236-64.